Akido Labs Secures $60 Million to Expand AI-Powered Healthcare Platform
Artificial intelligence and care delivery company Akido Labs Inc. has announced a $60 million funding round to grow its ScopeAI platform, designed to increase clinical capacity and improve healthcare access, particularly for underserved populations.
Founded in 2015, Akido combines AI-powered software with a network of multispecialty clinics to deliver efficient, whole-person care on a large scale. The company’s AI-driven clinical co-pilot, ScopeAI, assists medical assistants and physicians during patient visits by dynamically generating relevant clinical questions, capturing patient responses in real-time, and drafting documentation, including notes, diagnoses, and care plans.
ScopeAI operates as a reinforcement-learning system, learning and improving over time through feedback from its actions. This ongoing training loop refines the model’s accuracy, enabling it to adapt to clinical nuances while supporting faster, safer decision-making across diverse patient populations. By automating large portions of the intake and documentation process, ScopeAI allows providers to see more patients without compromising quality, expanding care access even in high-demand settings like street medicine programs and public clinics.
“We built ScopeAI to tackle the single biggest challenge facing healthcare systems worldwide: the physician shortage,” explains Prashant Samant, co-founder and CEO of Akido. “With demand for care far exceeding supply, AI is the key to addressing the global doctor deficit, empowering healthcare providers and ensuring patients receive timely, high-quality care regardless of financial means or geography.”
The Series B round was led by Oak HC/FT Partners LP, with participation from Greco Risk Partners, SNR Denton Group Ltd., and existing investors, including Y Combinator and Jeff Dean, chief scientist at Google DeepMind and Google Research.
“Akido is delivering on the promise of changing how patients experience a visit with their provider through AI,” said Andrew Adams, co-founder and managing partner at Oak HC/FT. “With its robust, longitudinal dataset, Akido has the refinement in its foundational model to offer clinical accuracy where others have struggled.”
